NCT04957485View on ClinicalTrials.gov

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Smallpox
Interventions
DRUG

Tecovirimat

oral antiviral

DRUG

Smallpox and Mpox Vaccine

vaccine

OTHER

Placebo

TPOXX Placebo

Trial Locations (2)

68134-3664

Meridian Clinical Research, Omaha

43213-6510

Aventiv Research Inc, Columbus

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

SIGA Technologies

INDUSTRY